Gentler transplant shows promise for kids with blood diseases

NCT ID NCT01050855

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer side effects than standard transplants. Researchers are tracking how well the donor cells take and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Reduced intensity conditioning regimen (Campath, Fludarabine, Melphalan, Busulfan, Cyclosporine, Cellcept)

What this could lead to

If successful, this could offer a safer transplant option for children with non-malignant blood disorders, reducing side effects and improving long-term survival.

What could go wrong

This is a mid-stage trial with only 75 participants, so results may not apply to everyone. The regimen still carries risks like graft failure or infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia bone marrow failure syndrome common variable immunodeficiency disease hemoglobinopathy hemophagocytic syndrome immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome immunodeficiency disease inborn error of immunity inherited hemoglobinopathy Langerhans cell histiocytosis macrophage activation syndrome severe combined immunodeficiency severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency sickle cell disease Wiskott-Aldrich syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States